Susan L. Kelley, M.D.

Vice President
Therapeutic Area Head Oncology
Bayer Pharmaceuticals Corporation

Dr. Kelley received her M.D. from Duke University School of Medicine and completed oncology training at the Dana-Farber Cancer Institute in Boston.  She accepted a position in Oncology and Clinical Pharmacology at the Yale Cancer Center in 1985.  She joined the Oncology Therapeutic Area at Bristol-Myers Squibb in 1987 to pursue oncology clinical research and drug development.  While at BMS, she participated in the development and registration of several new drug products, including teniposide, Taxol, didanosine (ddI) as well as supervising the clinical development programs for a cancer vaccine for melanoma, and numerous phase I and II early development projects.  She was also involved in the creation of the original BMS-Millennium collaboration on pharmacogenomics.  In 2001, she joined Bayer Pharmaceuticals in West Haven, Connecticut as Global Therapeutic Area Head for the newly created Oncology Therapeutic Area.  Since then she has been actively involved in all aspects of Oncology drug development, including the successful advancement of Nexavar^® (sorafenib) through the FDA approval process, with approval granted in December 1005.  She is responsible for Oncology portfolio management and supervises a group of oncology physicians and clinical project managers, based partly in the US and partly in Germany, which directs the global product development and clinical trial activities for the Bayer oncology pipeline.

February 2006